On paper, healthcare doesn’t look like an obvious playground for Big Tech. It’s heavily regulated, operationally messy, and deeply local. But in boardrooms from Seattle to Cupertino, healthcare is now being treated less like a “new vertical” and more like the next foundational platform shift the kind that can absorb decades of product innovation, cloud capacity, and AI R&D.
The timing isn’t accidental. Healthcare spend is vast and still rising: U.S. health spending grew 7.5% in 2023 to about $4.8 trillion, according to federal data cited by Reuters, and continued growth is projected over the coming decade. (Reuters) In the OECD’s latest comparisons, the U.S. spent 17.2% of GDP on health in 2024, far above peer economies a signal of both market size and inefficiency. (OECD) Globally, WHO reports health spending reached $9.8 trillion (10.3% of global GDP) in 2021. (World Health Organization)
That scale is exactly what attracts companies built to monetize infrastructure, networks, and data-driven workflows. But the deeper story is about where value is shifting inside healthcare away from stand-alone apps and toward integrated, AI-assisted systems that sit inside clinical work, consumer devices, and pharma research.
1) Healthcare is one of the last “offline” mega-industries and it’s full of tractable waste
Big Tech’s core playbook is to digitize fragmented processes, standardize them, and then monetize the rails: cloud, software platforms, marketplaces, and subscriptions.
Healthcare is still burdened by administrative complexity. Research and policy analyses regularly estimate that administrative spending is a large share of overall healthcare costs; Health Affairs, for instance, has cited 15–30% as a common range in the U.S. (healthaffairs.org) Whether the exact number is 15% or 30%, the point is the same: even small efficiency gains become tens of billions in addressable value.
This is why so much of Big Tech’s healthcare effort focuses on the unglamorous middle: documentation, claims, coding, scheduling, prior authorization, call centers, and clinical inbox overload.
2) Generative AI finally gives Big Tech a wedge that clinicians can feel in their day-to-day work
For years, digital health promised transformation and delivered patchwork. Generative AI changes the adoption curve because it targets the single biggest pain point in modern medicine: time.
McKinsey notes that healthcare organizations are moving from experimentation to scaled implementations of generative AI across operations and stakeholder engagement. (McKinsey & Company) The “killer app” is not chatbots for patients (though those exist); it’s ambient documentation, clinical summarization, and workflow copilots that reduce administrative burden without forcing clinicians to learn yet another system.
That logic explains why Microsoft has leaned so hard into healthcare AI via its cloud stack and Nuance’s clinical documentation tooling, and why it has deepened collaborations with dominant EHR platforms like Epic to bring generative AI into the workflow layer clinicians already use. (Microsoft)
And it explains why partnerships now include not just models, but trusted content: Reuters reported Harvard Medical School licensed consumer health content to Microsoft to improve the quality of health responses in its Copilot experience. (Reuters)
3) Cloud platforms are racing to become the “operating system” of hospitals and health systems
The quiet competition isn’t only Amazon vs Apple vs Google. It’s AWS vs Azure vs Google Cloud each trying to be the default substrate where healthcare data lives, where AI runs, and where compliance is packaged as a product.
Google Cloud, for example, has been pushing healthcare-specific AI search and summarization that can work across clinical notes and multiple data sources, expanding into multimodal inputs (including images and other complex data types) capabilities it showcased around HIMSS 2025. (Healthcare Dive)
Once a cloud provider becomes deeply embedded hosting EHR workloads, imaging, analytics, and AI tooling switching costs rise dramatically. Healthcare IT is sticky, and stickiness is what Big Tech monetizes best.
4) Consumer devices have turned health into a daily habit and Apple is the blueprint
Apple’s healthcare strategy is often misunderstood. It’s not trying to become a hospital. It’s turning the iPhone-and-Watch ecosystem into a continuous sensor layer that can feed prevention, early alerts, and clinical research.
Regulatory milestones matter here. In 2024, the FDA qualified Apple’s AFib History Feature as a Medical Device Development Tool (MDDT) for use in clinical studies a step that strengthens the legitimacy of consumer-grade digital biomarkers in regulated research contexts. (American College of Cardiology)
More recently, Apple’s health feature roadmap has moved toward hypertension detection: Reuters reported FDA clearance for an Apple Watch hypertension feature and described how the system analyzes optical sensor data over time rather than acting as a direct blood pressure cuff replacement. (Reuters)
The business logic is powerful: health features increase device retention, expand services opportunities, and position Apple as a trusted consumer health interface the kind of trust money can’t easily buy in healthcare.
5) Amazon is betting on an end-to-end “care + pharmacy + logistics” flywheel
If Apple’s advantage is sensors and consumer trust, Amazon’s advantage is fulfillment and frictionless commerce which matters a lot in healthcare, where the patient journey is typically fragmented.
Amazon’s push has been expensive and iterative. It acquired primary care provider One Medical in a deal valued around $3.9B (company statement) and then began consolidating pieces of its virtual care offerings into that primary-care brand. (About Amazon) Reuters has also described Amazon’s continued restructuring and executive churn as it tries to turn a portfolio of health assets into a coherent operating model. (Reuters)
This is classic Amazon: build a system where discovery, consult, prescription, payment, and delivery can happen with minimal friction then scale it.
6) Drug discovery and life sciences are becoming an AI-and-compute arms race
Healthcare tech isn’t only about providers and patients. It’s also about pharma R&D, which is increasingly shaped by AI models, high-throughput simulation, and giant compute budgets.
A striking example surfaced this week at the JPMorgan Healthcare Conference: Reuters reported Nvidia and Eli Lilly plan to spend $1 billion over five years on a joint AI research lab aimed at accelerating drug discovery and development. (Reuters)
Big Tech loves this space because it rewards what they already dominate: chips, cloud, developer platforms, and AI tooling. If AI can shave even a fraction off R&D timelines, the downstream value is enormous.
7) Healthcare data is the most valuable dataset Big Tech can’t casually monetize which is exactly why it matters
Healthcare data is rich, longitudinal, and deeply predictive but it’s also sensitive, legally constrained, and reputationally explosive.
That paradox creates a moat. Companies that can build trusted, compliant data platforms and prove they can use AI safely earn relationships that smaller startups struggle to secure. This is also why Big Tech increasingly emphasizes “responsible AI,” security, and governance in healthcare messaging: the buyer is risk-averse, and the regulator is always nearby.
The catch: healthcare punishes hype
For every success story, healthcare has a long list of tech disappointments. The sector moves slowly, outcomes are hard to measure, and the tolerance for error is low.
Even the most aggressive players have faced turbulence. Coverage of Amazon’s One Medical leadership transition highlighted challenges such as restructuring and scrutiny around patient safety as the company scales its care delivery ambitions. (The Washington Post)
The winners in this cycle won’t be the companies with the flashiest demos. They’ll be the ones that can show, quarter after quarter:
- Measurable clinician time saved
- Fewer documentation errors and safer handoffs
- Faster access to relevant patient context
- Cleaner billing and less administrative churn
- Real-world evidence that AI systems behave reliably under clinical constraints
What comes next
If 2020–2023 was “digital front doors” and telehealth, and 2024–2025 was “genAI pilots,” then 2026 is shaping up to be the year healthcare buyers demand proof and vendors respond with deeper integration:
- Multimodal clinical search (notes + labs + imaging + genomics) (Fierce Healthcare)
- Ambient documentation embedded into EHR workflows (Microsoft)
- Regulated digital biomarkers from consumer devices feeding trials and longitudinal monitoring (American College of Cardiology)
- AI-first drug discovery partnerships driven by compute and foundation models (Reuters)
Big Tech isn’t investing in healthcare because it’s easy. It’s investing because healthcare is where the next decade of AI, cloud, devices, and data governance converges and because the prize isn’t a single product. It’s owning the rails that healthcare runs on.
